Human TSLP R (Luc) HEK293 Reporter Cell
描述（Description）
The Human TSLP R (Luc) HEK293 Reporter Cell was engineered to not only express STAT5 signaling response element, but also express the receptors full length human TSLP R (Gene ID: 64109) and IL-7 R alpha (Gene ID: 3575). When stimulated with human TSLP protein, the TSLP/TSLP R interaction drives STAT5-mediated luminescence. Inhibition of TSLP binding to TSLP R by either anti-TSLP or anti-TSLP R antibodies results in a decrease in luminescence.
應(yīng)用說明（Application）
Screen for anti-human TSLP or anti-human TSLP R neutralizing antibody
生長特性（Growth Properties）
Adherent
篩選標(biāo)記（Selection Marker）
Zeocin (100 μg/mL) + Puromycin (2 μg/mL)
培養(yǎng)基（Culture Medium）
DMEM medium + 10% FBS
凍存液（Freeze Medium）
Serum-free cell cryopreservation medium
裝量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存儲（Storage）
Frozen in liquid nitrogen.
支原體檢測（Mycoplasma Testing）
Negative
無菌檢測（Sterility Testing）
Negative
使用說明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
Thymic stromal lymphopoietin (TSLP) is a pleiotropic cytokine and takes multi-functions via binding to a high-affinity heteromeric complex composed of thymic stromal lymphopoietin receptor (TSLPR) chain and IL-7Rα. The receptor complex on cells co-expressing TSLPR and IL-7Rα activated downstream genes expression and initiate proinflammatory signaling. TSLP involved in a variety of allergic diseases (e.g., atopic dermatitis, bronchial asthma). Further investigation indicated that TSLP is also involved in chronic inflammatory (i.e., chronic obstructive pulmonary disease and celiac disease) and autoimmune (e.g., psoriasis, rheumatoid arthritis) disorders and several cancers.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關(guān)鍵字： TSLPR報(bào)告細(xì)胞系;TSLPR報(bào)告細(xì)胞株;TSLP R細(xì)胞系;TSLP R細(xì)胞株;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。